NovAliX's Graffinity Pharmaceuticals will use its Graffinity fragment-based screening technology to discover and develop small molecule compounds against an undisclosed target from Galapagos

NovAliX S.A.S.

France / Tools, Services, and Manufacturing

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Galapagos N.V.

Belgium / Small-Cap Biopharma (<$1 billion)

$234.9m on 09/02/2011 [market cap]

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced